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The impact of mycophenolate mofetil (MMF) on initial renal
transplant function is not well characterized. We tested how
MMF may modulate graft function and survival in a
syngeneic rat kidney transplantation model after prolonged
cold preservation. Donor kidneys were preserved in
University of Wisconsin for either 24 or 39 h prior to
transplantation into nephrectomized rats. Recipients received
MMF (20 mg/kg/day) or vehicle. Mycophenolic acid (MPA)
blood concentrations were measured by high-performance
liquid chromatography. The inflammatory response, tubular
epithelial proliferation, and histologic damage 3 days
post-transplantation were assessed microscopically. In the
24 h cold storage (c.s.) group serum-creatinine was measured.
In the 39 h c.s. group 1-week recipient survival was
determined. After 24 h of c.s., recipient survival was 100%.
The number of T-cell infiltrates was low and not influenced
by MMF, whereas renal ED1þ cell infiltration was
significantly suppressed by MMF. Tubular cell proliferation
was enhanced by MMF. Serum-creatinine levels and renal
histology were comparable between MMF and
vehicle-treated animals. In the 39 h c.s. group, recipient
survival was 20% in MMF-treated vs 90% in vehicle-treated
animals (P¼ 0.001). MMF effectively suppressed
inflammatory cell infiltration and inhibited tubular cell
proliferation. MMF-induced structural damage was most
striking in the renal papilla. In rat kidney grafts with
moderate preservation injury (24 h c.s.), MMF, given at an
immunosuppressive dose, showed predominantly
antiinflammatory effects without compromising graft
function. In grafts with severe preservation injury (39 h c.s.),
MMF caused irreversible structural damage and inhibited
tubular cell regeneration resulting in renal failure.
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Delayed graft function (DGF) often occurs after transplant-
ation of marginal kidneys.1,2 DGF increases short-term
morbidity of renal transplant patients and, more importantly,
reduces long-term graft survival. In addition to donor age,
prolonged cold preservation time represents a major risk
factor for the occurrence of DGF.3 Exposure to calcineurin-
inhibitors immediately after transplantation has been shown
to impair graft recovery and function by increasing afferent
arteriole vasoconstriction and directly enhancing renal
tubular damage.4–6 As antiproliferative agents such as
sirolimus and mycophenolate mofetil (MMF) are considered
non-nephrotoxic, they offer a theoretical advantage as a
calcineurin-inhibitor sparing strategy for DGF. Sirolimus has
been shown to impede tubular epithelial repair and
regeneration after ischemia–reperfusion injury (IRI) to native
kidneys.7 Recent data from both animal and human studies
caution against the use of sirolimus in the presence of
impaired initial graft function.8–10 Unlike sirolimus, MMF
has been reported to have beneficial effects after renal IRI.
When given to donors prior to the ischemic insult, MMF
preserves renal function and morphology,11 most likely due
to its anti-inflammatory properties. However, counter to
these anti-inflammatory effects, which may ameliorate IRI,
MMF has been shown to inhibit the proliferation of
regenerating tubular cells in vitro and in vivo.12 MMF has
an antiproliferative effect generated by its prodrug myco-
phenolic acid (MPA), a reversible inhibitor of the enzyme
inosine monophosphate dehydrogenase. Inosine monopho-
sphate dehydrogenase plays a key role in de novo purine
synthesis, a pathway on which lymphocytes are more
dependent than other eukaryotic cells.13 The relative
influence of anti-inflammatory vs antiproliferative effects
on renal graft function and morphology remains to be
determined.
Until now, the effects of MMF on renal IRI have been
studied exclusively in nontransplant models, where native
kidneys undergo temporary occlusion of the renal pedicle
followed by reperfusion. The pattern of regeneration and
proliferation after warm IRI suffered by native kidneys differs
from that of cold preservation injury suffered by transplanted
kidneys.14,15
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We have undertaken a study of the effect of MMF on
kidney graft inflammation, structure, tubular cell prolifera-
tion, and function after prolonged cold preservation to
provide data that may eventually be useful in clinical
transplantation.
RESULTS
MPA blood concentrations
MPA blood concentrations were measured on day 3 post-
transplantation in recipients of 24-h cold-stored grafts and in
recipients of 39-h cold-stored grafts (n¼ 4/group). One day
after the last MMF dose, MPA concentrations were as follows:
0.8770.11 mg/ml (24 h cold storage (c.s.)) vs 0.7170.08 mg/
ml (39 h c.s.). Differences between the two groups were not
statistically significant.
Inflammatory cell infiltration
Three days after transplantation T-lymphocyte counts in 24
and 39 h cold-stored grafts were low (Table 1). There was a
trend towards reduction of CD3þ cell infiltration in MMF-
treated animals vs untreated controls. This trend reached
statistical significance in the medulla of 39 h cold-stored
grafts (Table 1).
ED1þ cell infiltration was significantly increased in all
anatomic areas of all vehicle-treated animals compared to
sham operation (Figure 1a and b). MMF consistently reduced
Mo/MF (ED1þ ) infiltration in all microcompartments in
both cold storage groups, but reduction was more pro-
nounced in 39 h cold-stored grafts. Compared with vehicle
treatment, MMF significantly reduced Mo/MF infiltration in
both the medulla and papilla of 39 h cold-stored grafts
(Figure 1b) and in the cortex of 24 h cold-stored grafts
(Figure 1a).
Renal expression of transforming growth factor b1 and
monocyte chemoattractant protein-1
Localization of intragraft transforming growth factor b1
(TGF-b1) expression is shown in Figure 7. Quantitation of
TGF-b1 revealed no differences between MMF and vehicle-
treated groups. However, 39 h of cold storage induced
significantly higher TGF-b1 expression than 24 h of cold
storage in the cortex and medulla (Table 2). Positive staining
for monocyte chemoattractant protein-1 (MCP-1) was found
predominantly in distal tubular epithelial cells. No differences
were observed between experimental groups. Due to a
relatively faint signal quantitation using digital imaging was
not possible.
Tubular cell proliferation
Tubular cell proliferation was quantified by counting
proliferating cell nuclear antigen (PCNAþ ) cells (Figure 2a
and b). MMF treatment was associated with substantially
more tubular cell proliferation in the cortex and medulla
of 24 h cold-stored grafts (Figure 2a) compared with 39 h
Table 1 | Average number of intragraft CD3+ infiltrates 3 days
after transplantationa
Native
kidney
24 h cold storage
vehicle/MMF
39 h cold
storage vehicle/MMF
(N=5/group) (N=5/group)
Cortex 0 0.570.5/0 170.5/1.170.8
Medulla 0 0.370.2/0 0.670.2/070.1*
Papilla 0 0/0 0.470.2/0
MMF, mycophenolate mofetil.
aExpressed as the number of CD3+ cells per field of view at  400 magnification.
*P=0.03 between 39 h vehicle-treatment and 39 h MMF-treatment.
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Figure 1 | Infiltration of ED1-positive monocytes/macrophages in
MMF vs vehicle-treated grafts (n¼ 5/group). Differences between
treatment groups were as follows: 24 h cold preservation (a): cortex:
#P¼ 0.004, *P¼ 0.006; medulla: #P¼ 0.04; papilla: #P¼ 0.02,
þP¼ 0.03. 39 h cold preservation (b): cortex: #P¼ 0.015, þP¼ 0.02;
medulla: #P¼ 0.02, *P¼ 0.03; papilla: #P¼ 0.04, *P¼ 0.04 (one-way
analysis of variance with paired comparison).
Table 2 | Intragraft TGF-b1 expression 3 days after
transplantationa
Native kidney
24 h cold
storage vehicle/MMF
39 h cold
storage vehicle/MMF
(N=5/group) (N=5/group)
Cortex 471.2 1775.4/12.376.3$ 45.5710.8#/4977.8+
Medulla 4.972.7 18.477.1/24.574.6+$ 32.878.3#/45.974.7+
Papilla 1.370.4 28.177.3#/23.272.9+ 31.4712/26.373.6+
MMF, mycophenolate mofetil; TGF-b1, transforming growth factor b1.
aExpressed as the percentage of positive area per field of view at  400
magnification.
#Po0.05 vehicletreatment vs native.
+Po0.05 MMF treatment vs native.
$Po0.05 24 h cold storage vs 39 h cold storage.
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cold-stored grafts (Figure 2b). Proliferative activity in the
papilla was markedly different from that observed in the
cortex and medulla. In 24 h cold-stored grafts, in both
treatment groups, the papilla showed very little proliferative
activity (Figure 2a). However, significant differences were
seen in the papilla of 39 h cold-stored grafts between vehicle
and MMF treatment (Figure 2b).
Graft function as determined by serum-creatinine
Since recipients of 24 h cold-stored grafts all survived
transplantation, renal function was assessed by serial
serum-creatinine measurements on days 1, 3, and 6.
Although the serum-creatinine of MMF-treated animals
was consistently higher than that of vehicle-treated animals,
the differences did not reach statistical significance (Figure 3).
The creatinine levels of MMF-treated animals were however
significantly higher than those of sham-operated animals,
while those of vehicle-treated animals were not significantly
increased relative to the sham group.
Graft function as evidenced by recipient survival
We have previously reported the relationship between
recipient survival after bilateral nephrectomy and rat kidney
transplantation after cold preservation times between 24 and
48 h.8 In the present study, the impact of MMF on recipient
survival was assessed after 24 and 39 h of cold storage. We
observed 100% survival in all recipients of 24 h cold-stored
grafts (n¼ 6/group). However, in recipients of 39 h cold
stored grafts (n¼ 10/group), there was a significantly higher
incidence of recipient death after MMF treatment compared
to vehicle treatment (P¼ 0.001; Figure 4). Animals who did
not survive the 7-day observation period (80% MMF-treated
vs 10% vehicle-treated) were anuric with ruffled fur and
guarding upon abdominal palpation. Death typically oc-
curred between post-transplantation days 2 and 3. Immedi-
ately prior to death, creatinine was 5.0–6.0 mg/dl. All dead
animals underwent post-mortem examination, which did
not, in any case, reveal pathology such as intra-abdominal
hemorrhage, urine leak, pneumonia, or any other infection,
which may have contributed to or caused death. There was
no difference in body weight evolution between vehicle and
MMF-treated animals in the immediate peritransplant
period. All animals lost approximately 4–5% of their body
weight per day. All survivors gained weight after day 5.
#Sham vs vehicle; +sham vs MMF; *vehicle vs MMF
#+
+
*
*
0
5
10
15
20
25
30
35
40
Cortex Medulla Papilla
Cortex Medulla Papilla
PC
NA
+ 
ce
lls
/F
V Sham
Vehicle 24 h
MMF 24 h
Sham
Vehicle 39 h
MMF 39 h
a
##
+
*
n.s.
0
5
10
15
20
25
30
35
40
PC
NA
+ 
ce
lls
/F
V
b
Tubular cell proliferation
on day 3 post-transplant
Figure 2 | Quantitation of tubular cell proliferation in MMF
and vehicle-treated grafts (n¼ 5/group). Differences between
treatment groups were as follows: 24 h cold preservation
(a): cortex: þP¼ 0.01, *P¼ 0.006; medulla: #P¼ 0.045, þP¼ 0.027,
*P¼ 0.032. 39 h cold preservation (b): cortex: þP¼ 0.04; medulla:
#P¼ 0.047; papilla: #P¼ 0.006, *P¼ 0.006 (one-way analysis
of variance with paired comparison).
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Figure 3 | Serum-creatinine levels at 1, 3, and 6 days after
transplantation of 24 h cold-preserved kidneys (n¼ 6).
Differences between MMF and vehicle-treated animals were not
significantly different at any time point. one-way analysis of
variance paired comparison revealed significant differences between
MMF-treated and sham-operated animals (right nephrectomy) but
not between vehicle-treated and sham-operated animals.
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Figure 4 | Recipient survival after transplantation of 39 h
cold-stored kidneys treated with either MMF or vehicle
(n¼ 10/group). 1-week survival was significantly lower in the
MMF-treatment group compared to the vehicle-treatment group (20
vs 90%; P¼ 0.001).
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Tubular injury
Tubular injury on post-transplantation day 3 was assessed
semiquantitatively, and compared between treatment groups
(n¼ 5 per group). An ATN scoring system encompassing 5
degrees of histologic damage was used (Figure 5). Grafts
transplanted after 24 h of c.s. showed mild to moderate
structural damage in the cortex and medulla, while the
papilla remained essentially unaffected (Figure 5a). Grafts
transplanted after 39 h of cold storage demonstrated more
severe tubular injury, mainly affecting the medulla (Figure
5b). However, the papilla of 39 h cold-stored grafts exhibited
moderate injury after vehicle treatment, but irreversible
injury after MMF treatment (Figures 5b, 6a, and b). The
severe damage of the papillary collecting ducts (ducts of
Bellini) found after MMF treatment was always associated
with widespread necrosis of the medullary tubules.
Association between tubular cell proliferation, inflammation,
and tubular injury
Spearman correlations were used to identify associations
between inflammatory cell infiltration in the cortex and
medulla, and tubular cell proliferation in 24 h cold-preserved
kidney grafts. A strong inverse correlation between inflam-
mation (ED1þ cell count) and proliferative activity
(PCNAþ cell count) in the medulla of vehicle-treated
animals was found (r¼1.0; P¼ 0.001). We also tested for
an association between proliferation (PCNAþ cell count)
and structural damage (ATN score) in the papilla of 39 h
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Figure 5 | Acute tubular necrosis score. Tubular damage was
graded on a scale from 0 to 4 (0¼no abnormalities; 4¼near
total necrosis) and results are shown for two different
preservation times (24 and 39 h). Significant differences
between MMF and vehicle treatment (n¼ 5/group) were seen in the
papilla of 39 h cold- stored grafts. (*P¼ 0.02; Student’s t-test).
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Figure 6 | Histology of the renal papilla 3 days after
transplantation. (a and b) Cross-sectioned papillary collecting ducts
(ducts of Bellini) in 39 h cold-stored grafts. (a) Vehicle-treated
grafts show vital collecting duct epithelium, (b) while MMF-treated
grafts show a confluent area of complete papillary necrosis.
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Figure 7 | Localization of renal TGF-b1 3 days after
transplantation. Arrows show positive immunohistochemical
staining in cortical tubular epithelial cells (a) and papillary collecting
ducts (b) of 39 h cold-stored grafts (vehicle treatment).
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cold-preserved grafts of MMF-treated animals and similarly
found a strong inverse correlation (r¼1.0; P¼ 0.001).
DISCUSSION
In this study, we used a syngeneic, rat kidney transplant
model with prolonged cold storage to investigate the effect of
MMF treatment on recovery from preservation injury. Grafts
exposed to MMF showed strikingly different patterns of
recovery, strongly depending on the duration of cold
preservation.
Since animals undergo bilateral native nephrectomies at
the time of transplantation, our model is life supporting and
therefore suited to study direct effects of immunosuppressive
treatment on recovery from severe preservation injury. We
have previously defined the relationship between the dura-
tion of cold preservation in University of Wisconsin solution
and recipient survival. We found 100 and 83% survival after
24 and 39 h of cold storage, respectively.8
We chose to administer MMF at a dose of 20 mg/kg/day
because this dose prevents rejection in a rat allogeneic heart
transplant model.16 To prove adequate dose response after
administration of 20 mg/kg of MMF, blood concentration of
MPA, the active metabolite of MMF, was measured 24 h after
the last MMF dose. Mean MPA concentrations were not
significantly different between recipients of 24 h cold-stored
grafts and recipients of 39 h cold-stored grafts. Thus, it
appears that poor initial graft function, caused by prolonged
cold storage, does not impair MMF uptake and metabolism.
The immunosuppressive properties of MMF have been
attributed to inhibition of both lymphocyte proliferation and
activation. The strong anti-inflammatory effect of MMF has
been invoked as the mechanism of protection against warm
IRI, as shown by reduced T-lymphocyte (CD3þ ) and Mo/
MF (ED1þ ) infiltration in a model of native kidney IRI.11
As previously shown by Ysebaert et al. the first day after
warm ischemic injury is characterized by widespread tubular
necrosis, followed by tubular regeneration on day 2.
Leukocyte infiltration, mainly Mo/MF and CD4þ T-cells
was found to be highest during the regeneration phase,
between days 5 and 10 after warm ischemia.12
In experimental renal transplant models, the number of
cellular infiltrates has been shown to correlate with the
duration of cold ischemia time.17 After cold storage and
transplantation, significant neutrophil and Mo/MF infiltra-
tion typically occurs earlier than after warm ischemia
induced by renal pedicle clamping.18,19 In our model of
prolonged cold storage, events influencing graft survival
apparently occur within the first 3 days post-transplantation
(Figure 4).
We herein showed that on day 3 post-transplantation,
MMF effectively suppresses Mo/MF infiltration into cold-
preserved rat kidney grafts (Figure 1). As expected and
previously shown by others,19 intragraft T-cell counts were
low on day 3 post-transplantation. Nevertheless, MMF
significantly reduced T-cell infiltrates in the medulla of 39 h
cold stored grafts (Table 1). Due to their accumulation early
after transplantation, Mo/MF may be critical in determining
short- and long-term outcomes of renal transplants especially
in the context of substantial preservation reperfusion injury.
Macrophages may either activate postischemic repair pro-
cesses by producing growth-stimulating cytokines such as
TGF-b or augment inflammation by producing proinflam-
matory cytokines.20–23 Their precise role in this setting
remains to be determined and likely depends on the severity
of ischemic injury.
Gonzalez et al.24 showed that MMF treatment (20 mg/kg/
day) initiated 1 day after rat kidney warm IRI significantly
increased serum-creatinine after 15 min of ischemia, in-
creased the total number of necrotic tubular cells after 30 min
of ischemia, and reduced survival after 45 min of ischemia.
Our experiments yielded similar results with significantly
reduced survival in MMF-treated animals after transplant-
ation of 39 h cold-preserved kidneys (Figure 4). These parallel
results were observed in spite of different experimental
models (i.e. warm ischemia in native kidneys vs prolonged
cold ischemia and renal transplantation). Nevertheless, this
may imply that consequences of MMF treatment are not
related to the nature of ischemic injury but rather to its
severity.
Antiproliferative agents such as MMF and sirolimus are
generally considered to be non-nephrotoxic. While they do
not appear to exacerbate the injury itself, their antiprolifera-
tive properties may retard tubular regeneration, thereby
delaying functional recovery after ischemic or toxic da-
mage.7,25 This effect seems to correlate closely with the degree
of pre-existing renal injury.26 In the present study, MMF
treatment of 24 h cold-preserved grafts increased cortical and
medullary tubular proliferation. In contrast, MMF treatment
of 39 h cold-preserved grafts inhibited cortical and medullary
tubular proliferation. We believe that 24 h of cold storage
results in moderate preservation injury. In this setting, Mo/
MF infiltration correlated negatively with tubular cell
proliferation, suggesting that anti-inflammatory properties
of MMF could stimulate tubular epithelial regeneration. As
previously shown, suppressing Mo/MF infiltration after
ischemic renal injury enhances tubular cell proliferation.27,28
In our model, MMF-induced inhibition of epithelial cell
regeneration, most dramatically in the papilla, substantially
impairs graft function as evidenced by reduced survival rates
in bilaterally nephrectomized recipients of 39 h cold stored
grafts (Figure 4).
Recently, Oliver et al.29 showed that the renal papilla is a
niche for adult kidney stem cells, and that these cells are
probably involved in postischemic repair processes. It is
therefore possible that MMF not only causes papillary
damage with impaired short-term graft function but also
destroys a potential source of long-term renal regeneration.
TGF-b1 a profibrotic cytokine, which has been identified
in platelets, macrophages, and nearly all tissues including
kidneys,30 is thought to stimulate tubular cell regeneration
after renal ischemic injury.31 In our present study, intragraft
TGF-b1 expression was not influenced by MMF. We therefore
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failed to demonstrate a possible link between Mo/MF
infiltration, secretion of growth-stimulating cytokines, and
tubular proliferation following renal preservation reperfusion
injury. Qualitative staining for MCP-1, a proinflammatory
cytokine involved in renal IRI,32 revealed no differences
between experimental groups. No quantitation was under-
taken as the staining signal was too faint.
From the clinical perspective, it is of interest to compare
the results of our current experiments involving MMF to
those of similar experiments involving sirolimus.8 Both MMF
and sirolimus precipitated acute renal failure after extended
cold preservation and delayed recovery of renal function after
moderate preservation injury. These findings suggest that
both antiproliferative drugs exert a deleterious effect on
regenerating kidney grafts, the extent of which depends on
the severity of preservation reperfusion injury.
However, the pattern of tubular damage differs between
these two drugs. In 39 h cold-stored grafts, sirolimus
treatment resulted in a band-like area of necrosis encom-
passing nearly the entire outer stripe of the medulla,8 whereas
in 39 h cold-stored grafts exposed to MMF structural damage
was most prominent in the papilla. In renal grafts, papillary
necrosis is uncommon and we have no functional explana-
tion for this phenomenon (Figure 7).
Studies including our previous and present work suggest
that MMF may have less adverse effects on renal grafts with
moderate preservation reperfusion injury than sirolimus.
While the use of sirolimus is considered a risk factor for the
development of DGF,9,10 no such association has been
described for MMF.10,33
CONCLUSIONS
During the first 3 days after transplantation MMF, given at an
immunosuppressive dose, effectively reduced macrophages
infiltration into grafts transplanted after long periods of cold
storage. In renal grafts with moderate injury (24 h c.s.), MMF
treatment enhanced cortical and medullary tubular cell
regeneration and did not significantly improve or worsen
early graft function. In grafts with severe injury (39 h c.s.),
MMF caused irreversible structural damage and inhibited
epithelial cell regeneration, especially in the papilla, resulting
in significantly reduced recipient survival in a life-sustaining
transplant model. Whether the predominant effect of MMF is
anti-inflammatory or antiproliferative likely depends on the
severity of the underlying ischemic injury. Further studies to
elucidate the effect of inflammatory cells on tubular cell
regeneration early after renal preservation reperfusion injury
are warranted.
MATERIALS AND METHODS
Experimental design
We tested the effect of MMF on syngeneic rat kidney transplants
after moderate (24 h cold storage) preservation reperfusion injury
and after severe (39 h cold storage) preservation reperfusion injury.
In both groups, recipients were assigned to either morphological or
functional studies. For morphological studies, all recipients were
killed on day 3 post-transplantation, and renal grafts were removed
for further examination. Functional studies included either serial
serum-creatinine measurements (24 h cold storage) or assessment of
graft survival (39 h cold storage). All survivors were killed on day 7
post-transplantation.
Animal surgery
All animal protocols were reviewed and approved by the University
of California San Francisco Committee on Animal Research and
Animal Care was in agreement with the National Institutes of Health
guidelines for ethical animal research (National Institutes of Health
publication number 80-123, revised in 1985). Kidney donors and
recipients were inbred male Lewis rats (200–250 g; Charles River
Laboratories, Wilmington, MA, USA) housed under standard
conditions with free access to water and chow. All procedures were
performed under inhalation anesthesia with isoflurane. Left kidneys
were procured, flushed with ViaSpan University of Wisconsin (UW)
solution (Barr Laboratories, Pomona, NY, USA) and stored at 41C
for times as specified (24 vs 39 h).
Recipients underwent bilateral native nephrectomies followed by
heterotopic kidney transplantation using an established microsurgi-
cal technique.34 Briefly, end-to-side anastomoses between the renal
vessels and the recipient’s abdominal aorta and inferior vena cava
were created using continuous 8-0 nylon sutures; mean warm
ischemia time was 1771.2 min. An end-to-end uretero-ureterost-
omy was performed using interrupted 11-0 nylon suture. Fluid
resuscitation for the immediate peritransplant period was achieved
by instilling 5 ml of normal saline into the peritoneal cavity before
abdominal closure. In the sham-operation group, animals under-
went right nephrectomy. After recovery from anesthesia, animals
were transferred to the housing facility and followed for a maximum
of 7 days.
MMF administration
MMF stock solution (provided by Roche Pharma, Basel, Switzer-
land) was diluted with clean water and shaken vigorously to obtain a
suspension suitable for oral gavage. The first dose (20 mg/kg/day)
was administered 1 h after recovery from anesthesia; subsequent
doses were given at 24 h intervals thereafter. Rats in the vehicle
group received the same volume of clean water by daily gavage.
MPA blood levels
Plasma concentration of MPA, the active metabolite of myco-
phenolate mofetil, was determined by high-performance liquid
chromatography analysis. On day 3 post-transplantation, blood
samples were taken 24 h after the last MMF dose.
Graft function
In the 24-h preservation group, 1-week recipient survival was 100%
and serum-creatinine was measured on days 1, 3, and 6. Serum-
creatinine levels of sham-operated rats (right nephrectomy) served
as baseline controls. Blood samples (0.5 ml), taken from the
retroorbital plexus, were processed and measured on a Roche/
Hitachi - 747 chemistry auto analyzer using standard methods. In
the 39 h preservation group, graft function was assessed by recipient
survival.
Graft histology
For morphological studies, n¼ 5 renal grafts per group were
harvested 3 days post-transplantation. Paraffin sections (4 mm) were
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stained with hematoxylin and eosin and periodic acid-Schiff using
standard procedures. Two blinded observers examined and scored
kidney sections for acute tubular necrosis as previously described.17
The degree of renal damage was evaluated semiquantitatively using
an ATN score where 0 represented no abnormalities, and 1, 2, 3, and
4 represented slight (o20%), moderate (20–40%), severe (40–60%),
and near-total (460%) necrosis of the renal parenchyma,
respectively.
Immunohistochemistry
Monoclonal mouse antibodies (Abs) against the following antigens
were used: anti-CD3 (T-lymphocytes; Linaris, Wertheim, Germany),
anti-ED1 (endothelial 1 antigen on monocytes/macrophages;
Serotec, Oxford, UK) and anti-PCNA (proliferating cell nuclear
antigen, clone PC10; Zymed Laboratories Inc., San Francisco, USA).
For TGF-b1 and MCP-1 staining, a rabbit polyclonal immuno-
globulin and a goat polyclonal immunoglobulin (Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA) was used, respectively.
Immunohistochemistry was carried out on 2 mm paraffin
sections. ED1þ staining was performed using the Alkaline-
Phosphatase-Anti-Alkaline-Phosphatase method on paraffin sec-
tions after deparaffinization and rehydration. Sections were
incubated for 60 min at room temperature with primary Ab at
1:1000 dilution in RPMI (Seromed, Heidelberg, Germany) with 10%
fetal calf serum and 3% bovine serum albumin. Fast Red Kit
(DakoCytomation, Hamburg, Germany) was used for detection and
visualization.
CD3, PCNA, TGF-b1, and MCP-1 staining was performed using
the standard avidin-biotin-complex method (Dako). Sections were
deparaffinized in xylol, rehydrated through graded alcohols, and
cooked in citrate buffer (pH 6.0) for 5 min. Slides were then cooled
to room temperature in phosphate-buffered saline (pH¼ 7.4) and
then incubated with primary Ab for either 60 min at room
temperature (CD3 diluted at 1:50; PCNA diluted at 1:100) or
overnight (TGF-b1 diluted at 1:200; MCP-1 diluted at 1:25) in Ab-
diluent (Dako). AEC-chromogen (Dako) was used for visualization.
Sections incubated with corresponding isotype controls instead of
primary Ab were used as negative controls.
Two observers who were blinded for the experimental conditions
evaluated renal infiltration of CD3þ and ED1þ cells and tubular
epithelial cell proliferation (PCNA) using a light microscope (Zeiss
Axio Imager A1, Jena, Germany). TGF-b1 expression was evaluated
using a digital imaging system (Zeiss axiocam HR with axiovision
4.4 software). In each microcompartment (cortex, medulla and
papilla) 10–15 randomly chosen field of views per section were
evaluated. The means for five rats at any time point were then
grouped together to obtain a final mean7s.e.m. Positive cell
staining for the respective monoclonal antibody was expressed as
mean7s.e.m. of cells per field of view or as the percentage of
positive area in one field of view at  400 magnification.
Statistical analyses
Means7s.e.m. were compared using the two-tailed Student’s t-test
for two groups and one-way analysis of variance with paired
comparisons for more than two groups. Survival was determined by
the Kaplan–Meier method and differences between groups were
assessed using the log-rank test. The association between inflam-
matory cell infiltration, tubular injury, and tubular cell proliferation
was determined using two-tailed Spearman bivariate correlation.
P-values of less than 0.05 were considered significant. All statistical
tests were performed using SPSS 10.0 for Windows (SPSS, Inc.,
Chicago, IL, USA).
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